Karuna to pay $15M upfront in licensing deal for potential mental disorder drugs

Feb. 02, 2023 8:29 AM ETKaruna Therapeutics, Inc. (KRTX)By: Ravikash, SA News Editor

Shot of a businessman and businesswoman shaking hands in a modern office

Delmaine Donson

  • Karuna Therapeutics (NASDAQ:KRTX) signed an agreement to get global development, manufacturing, and sale rights to Goldfinch Bio's investigational transient receptor potential canonical 4 and 5 (TRPC4/5) channel candidates, including lead drug GFB-887.
  • Karuna plans to evaluate these

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.